FDA accepts Merck HPV vaccine for review

The FDA has accepted for review Merck's (MRK) biologics license application for V503, a vaccine for human papillomavirus (HPV), a sexually transmitted virus that can cause cervical and other cancer.

V503 is designed to provide protection against the four HPV strains that Merck's Gardasil protects against plus five additional cancer-causing types of the virus. Trial data appears to support the new vaccine's efficacy. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs